ArticleAnnals of Indian Academy of Neurology2009
Management of acute exacerbations in multiple sclerosis.
Article in Annals of Indian Academy of Neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of tolebrutinib in multiple sclerosis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Pooled it
- Article
- Review
- Patterns of multiple sclerosis presentation to the emergency department.Frontiers in neurology · 2024Article
- Tumefactive multiple sclerosis.Proceedings (Baylor University. Medical Center) · 2024Article
- Multiple Sclerosis-A Demyelinating Disorder and Its Dental Considerations-A Literature Review with Own Case Report.Brain sciences · 2023Review
- Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General Neurologist.Journal of clinical neurology (Seoul, Korea) · 2023Review
- Immunomodulatory Aspects of Therapeutic Plasma Exchange in Neurological Disorders-A Pilot Study.International journal of molecular sciences · 2023Article
- Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.Journal of neuroinflammation · 2022Observational
- Predictors of progression from a first demyelinating event to clinically definite multiple sclerosis.Brain communications · 2022Article
- Current Utilization and Research Status of Traditional East Asian Herbal Medicine Treatment for Multiple Sclerosis: A Scoping Review.Frontiers in neurology · 2021Article
- Amnion-Derived Multipotent Progenitor Cells Suppress Experimental Optic Neuritis and Myelitis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?Frontiers in immunology · 2020Review
- Emergency Department MRI Scanning of Patients with Multiple Sclerosis: Worthwhile or Wasteful?AJNR. American journal of neuroradiology · 2017Article
- Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®).Advances in therapy · 2016Article
- VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.Cellular and molecular neurobiology · 2015Article
- The Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse Care.Multiple sclerosis international · 2015Article
- Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.Therapeutic advances in neurological disorders · 2014Review
- Rehabilitation interventions for the management of multiple sclerosis relapse: a short scoping review.International journal of MS care · 2014Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A key component of multiple sclerosis is the occurrence of episodes of clinical worsening with either new symptoms or an increase in older symptoms over a few days or weeks. These are known as exacerbations of multiple sclerosis. In this review, we summarize the pathophysiology and treatment of exacerbations and describe how they are related to the overall management of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.